Core Viewpoint - Heng Rui Medicine (1276.HK) experienced a 5.21% increase in stock price to 80.8 HKD following the announcement of the approval for its innovative oral diabetes medication, marking a significant milestone in the Chinese pharmaceutical market [1] Company Summary - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its product, HR20031 tablets, which is the first self-developed oral combination therapy for type 2 diabetes in China [1] - The product is designed for adult patients with type 2 diabetes who have inadequate blood sugar control despite treatment with metformin [1] Industry Summary - According to a report from Galaxy Securities, the pharmaceutical sector has undergone a prolonged valuation adjustment but is now showing a significant structural recovery trend [1] - Public fund holdings in the pharmaceutical sector remain below historical averages, indicating potential for growth [1] - The policy environment supporting the development of commercial insurance is expected to lead to marginal improvements in payment systems by 2025, benefiting innovative drugs and medical devices [1] - The outlook for the pharmaceutical industry remains positive, with continued interest in innovative drug business development (BD) and a potential revival in pharmaceutical investment and financing [1]

Core Viewpoint - Heng Rui Medicine (1276.HK) experienced a significant increase of 5.21% to HKD 80.8 following the announcement of the approval for its innovative diabetes medication, marking a positive development for the company and the pharmaceutical sector in China [1] Company Summary - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its product, HR20031 tablets, which is the first domestically developed oral hypoglycemic combination drug in China [1] - The HR20031 tablets are designed to improve blood sugar control in adult patients with type 2 diabetes who have inadequate control with metformin hydrochloride [1] Industry Summary - According to a report from Galaxy Securities, the pharmaceutical sector has undergone a prolonged valuation adjustment but is now showing a significant structural recovery trend [1] - Public fund holdings in the pharmaceutical sector remain below historical averages, indicating potential for growth [1] - With supportive policies for commercial insurance development expected to improve payment conditions by 2025, innovative drugs and medical devices are likely to benefit [1] - The outlook for the pharmaceutical industry remains positive, with continued interest in innovative drug business development (BD) and a potential revival in pharmaceutical investment and financing [1]

Major Events - Cambridge Technology (06166) sets the offer price for H-shares at HKD 68.88 per share [1] - Sany Heavy Industry (06031) sets the offer price for H-shares at HKD 21.30 per share [1] - Hengrui Medicine (01276) receives approval for the launch of HR20031 tablets [1] - Shanghai Pharmaceuticals (02607) subsidiary becomes the holder of the marketing authorization for amisulpride orally disintegrating tablets [1] - Fosun Pharma (02196) receives registration approval for Delarobert tablets and Delarobert granules [1] - WuXi AppTec (02359) plans to sell 100% equity of Kande Hongyi and Jinshi Medicine [1] - Hengfu Holdings (00643) receives a buyout offer at a discount of approximately 79.20% and will resume trading on October 27 [1] Operating Performance - Chifeng Jilong Gold Mining (06693) reports Q3 net profit of CNY 951 million, a year-on-year increase of 140.98% [1] - WuXi AppTec (02359) reports a net profit of CNY 12.076 billion for the first three quarters, up 84.84% year-on-year [1] - Huaxin Cement (06655) reports a net profit of CNY 2.004 billion for the first three quarters, a year-on-year increase of 76.01% [1] - Luoyang Molybdenum (03993) reports a net profit of approximately CNY 14.28 billion for the first three quarters, up 72.61% year-on-year [1] - Goldwind Technology (02208) reports a net profit of approximately CNY 2.584 billion for the first three quarters, a year-on-year increase of 44.21% [1] - CITIC Securities (06030) reports a net profit of approximately CNY 23.159 billion for the first three quarters, up 37.86% year-on-year [1] - Kingdee International (00268) reports annual recurring revenue of approximately CNY 3.86 billion from subscription services for the first three quarters, a year-on-year increase of about 18% [1] - China Nonferrous Mining (01258) estimates a profit of approximately USD 356 million for the first three quarters, a year-on-year increase of about 13% [1] - Chongqing Bank (01963) reports a net profit of CNY 4.879 billion for the first three quarters, a year-on-year increase of 10.19% [1] - China Resources Cement (01313) reports a profit attributable to shareholders of CNY 331 million for the first three quarters, a year-on-year increase of 7.3% [1] - China Shenhua Energy (01088) reports a net profit of CNY 41.366 billion for the first three quarters, a year-on-year decrease of 13.8% [1] - Haohai Biological Technology (06826) reports a net profit of approximately CNY 305 million for the first three quarters, a year-on-year decrease of 10.63% [1] - Great Wall Motors (02333) reports a net profit of CNY 2.298 billion for the third quarter, a year-on-year decrease of 31.23% [1] - China Heart and Heart Fertilizer (01866) reports a net profit of approximately CNY 800 million for the first three quarters, a year-on-year decrease of 47.86% [1] - China National Building Material (03323) reports a net profit of CNY 2.96 billion for the first three quarters [1] - GAC Group (02238) reports a net loss of approximately CNY 4.312 billion for the first three quarters, a shift from profit to loss year-on-year [1] - China Overseas Development (00688) reports revenue of CNY 103 billion and operating profit of CNY 13.15 billion for the first three quarters [1] - Haifeng International (01308) reports revenue of approximately USD 2.459 billion for the first three quarters, a year-on-year increase of approximately 16.6% [1] - China Energy Engineering (03996) reports a cumulative new contract amount of CNY 992.775 billion for the first three quarters, a year-on-year increase of 0.4% [1] E-commerce Performance - Li Ning (02331) reports high double-digit growth in its e-commerce virtual store business for the third quarter [2]

Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for its innovative oral diabetes medication, marking a significant advancement in the treatment of type 2 diabetes in China [1] Group 1: Product Information - The approved product is named Henggeli Jing Ruige Liting Metformin Sustained-Release Tablets (I) and (II) [1] - It is the first self-developed fixed-dose combination of three oral hypoglycemic agents in China [1] - The product is classified as a chemical drug of category 2.3, with specifications of 5/50/750 mg and 10/100/1000 mg [1] Group 2: Indications and Usage - The approved indication for the product is to improve blood sugar control in adult patients with type 2 diabetes who have inadequate blood sugar control with metformin hydrochloride, in conjunction with diet and exercise [1] - It is categorized as a prescription drug [1]

Group 1 - Company announced that its subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the launch of HR20031 tablets, which is China's first self-developed oral hypoglycemic combination fixed-dose formulation [1] - HR20031 tablets consist of three active ingredients: Prandial Glucose Regulators, Regaglitin, and Metformin, and are intended for adult patients with type 2 diabetes who have inadequate blood sugar control after Metformin treatment [2] - The product aims to simplify the treatment regimen by reducing the number of medications taken, thereby improving patient adherence to therapy [2] Group 2 - Diabetes has become the third most serious chronic disease affecting human health, with a prevalence rate of 13.79% among adults in China, translating to approximately 148 million patients [2] - The blood sugar control rate among type 2 diabetes patients is only 50.1%, indicating a significant need for effective treatment options [2] - The total research and development investment for HR20031 tablets has reached approximately 189.24 million yuan [2]

Company Summary - Heng Rui Medicine has received approval from the National Medical Products Administration for its HR20031 tablet, which is the first self-developed oral hypoglycemic combination drug in China [1] - The HR20031 tablet combines three active ingredients: empagliflozin, regaglitazone, and metformin, aimed at improving blood sugar control in adults with type 2 diabetes who have inadequate control with metformin alone [2] - The total R&D investment for the HR20031 project has reached approximately 189.24 million yuan [2] Industry Summary - Diabetes has become the third most serious chronic disease affecting human health, following cancer and cardiovascular diseases [2] - According to the International Diabetes Federation, the diabetes prevalence rate among Chinese adults (ages 20-79) is 13.79%, with approximately 148 million patients, making China the country with the highest number of diabetes patients [2] - The clinical medication adherence for type 2 diabetes patients is poor, with only 50.1% achieving adequate blood sugar control [2] - The HR20031 tablet aims to simplify the treatment regimen by reducing the number of medications needed, thereby improving patient adherence [2] - Currently, there are no similar combination drugs approved for sale in China, while a comparable product, TRIJARDY XR, is available internationally [2]

Core Viewpoint - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the launch of its oral hypoglycemic drug, HR20031, which is the first self-developed fixed-dose combination of three oral hypoglycemic agents in China [1] Company Summary - The approved product, HR20031, is a combination of empagliflozin, linagliptin, and metformin extended-release tablets [1] - It is indicated for adult patients with type 2 diabetes who have inadequate blood sugar control with metformin hydrochloride, in conjunction with diet and exercise [1] - This marks a significant milestone as there are currently no similar products approved for sale in the domestic market [1]